SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients

BACKGROUND: Cetuximab, an anti-EGFR monoclonal antibody, is used in combination with chemotherapy in clinic to enhance the outcome in metastatic colorectal cancer (mCRC) patients with only ~ 20% response rate. To date only activating mutations in KRAS and NRAS have been identified as poor prognosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Mei, Zhu, Shao, Yang W., Lin, Peinan, Cai, Xiaomin, Wang, Biao, Ding, Yan, Ma, Xiangyuan, Wu, Xue, Xia, Yewei, Zhu, Dongqin, Shu, Yongqian, Fu, Zan, Gu, Yanhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921972/
https://www.ncbi.nlm.nih.gov/pubmed/29703253
http://dx.doi.org/10.1186/s12885-018-4298-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921972/
https://www.ncbi.nlm.nih.gov/pubmed/29703253
http://dx.doi.org/10.1186/s12885-018-4298-5

Ejemplares similares